EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Respiratory-gated proton beam therapy for intrahepatic cholangiocarcinoma without fiducial markers

Akihito Okubo, Sae Matsumoto, Hiroyasu Tamamura, Yoshitaka Sato, Satoko Asahi, Hitoshi Tatebe, Kazutaka Yamamoto, Keiichiro Matsushita, Makoto Sasaki, Yoshikazu Maeda, Yuji Tameshige, Hajime Sunagozaka und 4 weitere

Radiation Oncology · 2024

DOI: 10.1186/s13014-024-02550-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Radiation Oncology, 2024. Verfasst von Akihito Okubo und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, 920-8641, Japan. aki3720720@yahoo.co.jp. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Proton Therapy, Bile Duct Neoplasms, Fiducial Markers. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is a challenging primary liver cancer with a poor prognosis, especially in unresectable cases. Traditional palliative irradiation is limited in reducing liver doses. This study aimed to evaluate the efficacy and toxicity of respiratory-gated proton beam therapy without fiducial markers for intrahepatic cholangiocarcinoma. METHODS: Between October 2011 and February 2022, 24 patients (median [range] age, 71 [41-88] years) were evaluated at our institution. Twelve patients were pathologically diagnosed with ICC. All patients underwent respiratory-gated proton beam therapy at a dose of 48-83.6 (relative biological effectiveness) in 20-38 fractions with four-dimensional computed tomography planning. The median follow-up period was 18.5 (range, 2.0-74.0) months. The median tumor size was 41 (range, 10-134) mm. Twenty-one patients were classified as having Child-Pugh class A, and three patients were classified as having Child-Pugh class B. Local progression was defined as any growth of the irradiated tumor. RESULTS: The median survival time was 28 months for all patients. The Kaplan-Meier estimates of the 2-year overall survival, progression-free survival, and local tumor control rates were 51%, 26%, and 73%, respectively. Local tumor control rates were non-inferior to those reported in previous studies using fiducial markers. One patient had grade 4 pleural effusion; however, whether this was an adverse event due to the proton beam therapy was unclear. CONCLUSIONS: Respiratory-gated proton beam therapy without fiducial markers is an effective and less invasive treatment option for ICC, showing potential for improved local control and tolerable adverse effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaProton TherapyBile Duct NeoplasmsFiducial MarkersHumansAgedMaleMiddle AgedFemaleAged, 80 and overAdultRadiotherapy Planning, Computer-AssistedRetrospective StudiesPrognosisSurvival Rate

Stichwörter der Autor:innen

4D-CTCholangiocarcinomaProton beam therapyRespiratory-gated irradiation

Autor:innen und Institutionen

  • Department of Radiology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, 920-8641, Japan. aki3720720@yahoo.co.jp.
  • Proton Therapy Center, Fukui Prefectural Hospital, Fukui, 910-8526, Japan.
  • Department of Gastroenterology, Fukui Prefectural Hospital, Fukui, 910-8526, Japan.
  • Department of Radiology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, 920-8641, Japan.
  • Department of Radiology, Kanazawa Medical University, Kahoku, Ishikawa, 920-0293, Japan.

Zitieren

APA

Okubo, A., Matsumoto, S., Tamamura, H., Sato, Y., Asahi, S., Tatebe, H., Yamamoto, K., Matsushita, K., Sasaki, M., Maeda, Y., Tameshige, Y., Sunagozaka, H., Aoyagi, H., Shibata, S., Takamatsu, S., & Kobayashi, S. (2024). Respiratory-gated proton beam therapy for intrahepatic cholangiocarcinoma without fiducial markers. Radiation Oncology. https://doi.org/10.1186/s13014-024-02550-2

Vancouver

Okubo A, Matsumoto S, Tamamura H, Sato Y, Asahi S, Tatebe H, et al. Respiratory-gated proton beam therapy for intrahepatic cholangiocarcinoma without fiducial markers. Radiation Oncology. 2024. doi:10.1186/s13014-024-02550-2

BibTeX
@article{Okubo2024,
  author = {Okubo, Akihito and Matsumoto, Sae and Tamamura, Hiroyasu and Sato, Yoshitaka and Asahi, Satoko and Tatebe, Hitoshi and Yamamoto, Kazutaka and Matsushita, Keiichiro and Sasaki, Makoto and Maeda, Yoshikazu and Tameshige, Yuji and Sunagozaka, Hajime and Aoyagi, Hiroyuki and Shibata, Satoshi and Takamatsu, Shigeyuki and Kobayashi, Satoshi},
  title = {Respiratory-gated proton beam therapy for intrahepatic cholangiocarcinoma without fiducial markers},
  journal = {Radiation Oncology},
  year = {2024},
  doi = {10.1186/s13014-024-02550-2}
}
Kostenlos starten →